A position statement of the Slovenian Association for Gastroenterology and Hepatology on the management of patients infected with Helicobacter pylori

  • Bojan Tepeš AM DC RogaškaPrvomajska 29a3250 Rogaška Slatina
  • Borut Štabuc UKC Ljubljana, KOGE
Keywords: SAGH recommendations, H. pylori, treatment, primary and secondary gastric cancer prevention

Abstract

The article presents a position statement of the Slovenian Association for Gastroenterology and Hepatology on the management of patients infected with Helicobacter pylori (H. pylori). Position statement was presented and adopted at the 64th SAGH meetting on 11 November 2016 in Portorož.

Every patient infected with H. pylori needs treatment. Recommended first-line regimen is a 14-day treatment with esomeprazole, amoxicillin and clarithromycin. The success of treatment must be monitored by non-invasive tests (urea breath test) one month or more after completing the treatment. When the first-line treatment fails, we recommend that patient is referred to a gastroenterologist. The recommended second-line therapy consists of a 14-day treatment with levofloxacin (esomeprazole, amoxicillin, levofloxacin), or 14 per day treatment with colloidal bismuth (esomeprazole, colloidal bismuth, oxytetracycline / amoxicillin, metronidazole). All third-line treatments should be based on the results of antibiotic susceptibility testing.

H. pylori is grade I carcinogen and is responsible for 89 % of all cancers of the stomach, with the exception of cancer of the cardia. Therefore, the SAGH recommends that we should start with a national screening programme for H. pylori infection in asymptomatic Slovenian population aged between 20 and 30 years. All H. pylori infected patients should be treated with a 14-day quadruple regimen (esomeprazole, colloidal bismuth, oxytetracycline / amoxicillin, metronidazole). The program must be organised and supervised along the lines of the SVIT programme.

Position statement is also given for secondary gastric cancer prevention in older patients with chronic H. pylori infection and diffuse preneoplastic gastric mucosa changes (atrophy and intestinal metaplasia).

Downloads

Download data is not yet available.

References

Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6–30.

Gubina M, Tepeš B, Vidmar G, Ihan A, Logar J, Wraber-Herzog B. Prevalenca protiteles proti bakteriji Helicobacter pylori v Sloveniji v letu 2005. Zdrav Vestn. 2006;75(3):169–73.

Tepeš B, Štabuc B. Priporočila slovenskega združenja za gastroenterologijo in hepatologijo za zdravljenje okužbe z bakterijo Helicobacter pylori. Zdrav Vestn. 2011;80(6):647–56.

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353–67.

Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016 Feb;43(4):514–33.

IARC/WHO. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC working group report. 2014(8) [2016 Aug 23]. Available from: https://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/Helicobacter_pylori_Eradication.pdf.

Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials.

Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):933–47.

Ferwana M, Abdulmajeed I, Alhajiahmed A, Madani W, Firwana B, Hasan R, et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol. 2015 Jan;21(4):1305–14.

Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol. 2006 Aug;101(8):1921–30.

Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013 Dec;19(45):8188–91.

Burucoa C, Delchier JC, Courillon-Mallet A, de Korwin JD, Mégraud F, Zerbib F, et al. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter. 2013 Jun;18(3):169–79.

Woo JS, el-Zimaity HM, Genta RM, Yousfi MM, Graham DY. The best gastric site for obtaining a positive rapid ureas test. Helicobacter. 1996 Dec;1(4):256–9.

Weston AP, Campbell DR, Hassanein RS, Cherian R, Dixon A, McGregor DH. Prospective, multivariate evaluation of CLOtest performance. Am J Gastroenterol. 1997 Aug;92(8):1310–5.

Tepeš B, Zidar N. Priporočila za endoskopsko in histološko spremljanje bolnikov s kroničnim gastritisom in predkancerozami želodca. Zdrav Vestn. 2014;83(2):93–101.

Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W, et al. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med. 2010;49(12):1103–9.

Tepeš B, Križman I. Priporočila za zdravljenje okužbe z bakterijo Helicobacter pyori v Sloveniji. Zdrav Vestn. 1998;67(3):159–62.

Ford AC, Qume M, Moayyedi P, Arents NL, Lassen AT, Logan RF, et al. Helicobacter pylori “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology. 2005 Jun;128(7):1838–44.

Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006 Apr;(2):CD002096.

Štabuc B, Tepeš B, Skok P, Vujasinović M, Blinc A, Čerček M, et al. Smernice za preprečevanje in zdravljenje neželenih učinkov nesteroidnih protivnetnih in antiagregacijskih učinkovin na prebavila. Zdrav Vestn. 2015;84(1):3–15.

Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002 Jan;359(9300):14–22.

Sostres C, Carrera-Lasfuentes P, Benito R, Roncales P, Arruebo M, Arroyo MT, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol. 2015 May;110(5):684–9.

Kuipers EJ, Uyterlinde AM, Peña AS, Hazenberg HJ, Bloemena E, Lindeman J, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995 Sep;90(9):1401–6.

Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. European Helicobacter Study Group. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646–64.

Yuan W, Li Yumin, Yang Kehu, Ma Bin, Guan Quanlin, Wang D, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010 Jun;45(6):665–76.

Goddard AF, James MW, McIntyre AS, Scott BB; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011 Oct;60(10):1309–16.

Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan;115(2):168–86.

Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013 May;368(21):2041–2.

Tepeš B, Ojsteršek Z. Uspešnost zdravljenja okužbe s Helicobacter pylori v Sloveniji v letu 2008. Zdrav Vestn. 2010;79(1):19–24.

Vujasinović M, Jeverica S, Roba N, Dolinar U, Tepeš B. Uspešnost zdravljenja okužbe z bakterijo Helicobacter pylori v koroški regiji. Zdrav Vestn. 2013;83(1):36–44.

Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016 Feb;43(4):514–33.

Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007 Dec;45(12):4006–10.

Karamanolis GP, Daikos GL, Xouris D, Goukos D, Delladetsima I, Ladas SD. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. Digestion. 2014;90(4):229–31.

Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013 Jan;62(1):34–42.

Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2016 Jun;28(6):676–83.

Mc Nicholl AG, Gasbarini A, Tepeš B, Lerang F, Bordin DS, Schvets O, et al. Pan –European registry on H. pylori management (HP-EUREG) first line treatments. Helicobacter. 2014;19 Suppl 1:129.

Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008 Oct;28(7):868–77.

Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014 Aug;20(30):10338–47.

Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007 Oct;147(8):553–62.

Flores HB, Salvana A, Ang EL, Grilli D, Magrini N, Bazzoli F. Duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Gastroenterology. 2010 May;138(5):S-340.

Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):79–88.

Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999 Oct;159(19):2312–6.

Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013 May;14(7):843–61.

Jeverica S, Tepeš B, Ihan A, Skvarč M. Primarna odpornost bakterije Helicobacter pylori. Zdrav Vestn. 2010;79(1):25–30.

Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003 Mar;98(3):562–7.

Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, et al. Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar;377(9769):905–13.

Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015;13(9):1616–24.

Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012 Jan;35(2):209–21.

Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008 Sep;14(35):5385–402.

Macy E. Penicillin allergy: optimizing diagnostic protocols, public health implications, and future research needs. Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):308–13.

Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection — a critical review. Aliment Pharmacol Ther. 2004 Nov;20(10):1001–17.

Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015 Jan;136(2):487–90.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108.

Zadnik V, Bračko M, Hočevar M, Jarm K, Pompe Kirn V, Žakelj Primic M, et al.Rak v Sloveniji v 2013. Ljubljana: Onkološki inštitut, Register raka Republike Slovenije; 2016.

Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975 Jul;2(7924):58–60.

Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.

Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat. 1999;14(3):249–55.

Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, et al. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007 Jun;98(6):790–4.

Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol. 2007 Aug;102(8):1789–98.

Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991 Oct;325(16):1127–31.

Yamaguchi H, Goldenring JR, Kaminishi M, Lee JR. Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci. 2002 Mar;47(3):573–8.

Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol. 2000 Feb;24(2):167–76.

de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007 Feb;12(1):1–15.

Tepeš B, Kavčič B, Zaletel LK, Gubina M, Ihan A, Poljak M, et al. Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication. J Pathol. 1999 May;188(1):24–9.

Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000 Jul;119(1):7–14.

Rocco A, Suriani R, Cardesi E, Venturini I, Mazzucco D, Nardone G. Gastric atrophy and intestinal metaplasia changes 8 years after Helicobacter pylori eradication. A blind, randomised study. Minerva Gastroenterol Dietol. 2002 Jun;48(2):175–8.

Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002 Aug;16(8):1449–56.

Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl). 2003 Jan;116(1):11–4.

Lu B, Chen MT, Fan YH, Liu Y, Meng LN. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol. 2005 Nov;11(41):6518–20.

Salih BA, Abasiyanik MF, Saribasak H, Huten O, Sander E. A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. Dig Dis Sci. 2005 Aug;50(8):1517–22.

Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005 Nov;54(11):1536–40.

Arkkila PE, Seppälä K, Färkkilä MA, Veijola L, Sipponen P. Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study. Scand J Gastroenterol. 2006 Jul;41(7):782–90.

Take S, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol. 2015 Jun;50(6):638–44.

Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):639–42.

Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004 Jan;291(2):187–94.

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008 Aug;372(9636):392–7.

Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, et al. Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis. PLoS One. 2015 Apr;10(4):e0124725.

Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013 May;62(5):676–82.

Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012 Mar;104(6):488–92.

Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol. 2008 Mar;103(3):510–4.

Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016 May;150(5):1113–1124.e5.

Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 2002 Mar;50(3):378–81.

de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008 Apr;134(4):945–52.

Tepeš B. Kavalar R. Želodčni rak, možnosti presejanja in predlog za endoskopsko in histološko sledenje bolnikov z predrakavimi spremembami sluznice želodca. Zdrav Vestn. 2010;79(4):366.74.

Tepeš B, Zidar N. Priporočila za endoskopsko in histološko spremljanje bolnikov s kroničnim gastritisom in predkarcinozamo želodca. Zdrav Vestn. 2014;83(2):93–101.

Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012 Jan;44(1):74–94.

Published
2018-04-21
How to Cite
1.
Tepeš B, Štabuc B. A position statement of the Slovenian Association for Gastroenterology and Hepatology on the management of patients infected with Helicobacter pylori. TEST ZdravVestn [Internet]. 21Apr.2018 [cited 28Mar.2024];87(3-4):176-90. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2615
Section
Professional Article